Drugs / Zabadinostat
Zabadinostat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07488884 | Jun 2026 → Jun 2027 expected | pancreatic ductal adenocarcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT01977638 | Feb 2014 → Oct 2019 | cancer of unknown primary site | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03873025 | Oct 2019 → Apr 2024 | diffuse large B-cell lymphoma | University College, London | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03993626 | May 2018 → Dec 2019 | colorectal cancer | Celleron Therapeutics Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05873244 | Aug 2023 → Dec 2027 expected | hepatocellular carcinoma | Stephen Chan Lam | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zabadinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05873244 ↗ |
| Known as | Azd-9468 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297489 ↗ |
| Known as | CXD101 | “Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks” NCT05873244 ↗ |
| Known as | Hdac inhibitor cxd101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297489 ↗ |
| Known as | Hdac-in-4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297489 ↗ |
| Action | Inhibit | “a novel histone deacetylase inhibitor” NCT01977638 ↗ |
| Modality | Small molecule | — CHEMBL4297489 ↗ |
| Route | Oral | “Capsules, administered orally” NCT01977638 ↗ |